Nouvelle déclaration d'incident
No de la demande: 2017-0689
Numéro de référence du titulaire d'homologation: 2017KP010
Nom du titulaire (nom légal complet, aucune abbréviation): Bayer Inc
Adresse: 2920 matheson BLVD
Ville: Mississaugua
État: ON
Pays: Canada
Code postal /Zip: L4W 5R6
Incident chez un animal domestique
Pays: UNITED STATES
État: UNKNOWN
ARLA No d'homologation ARLA No de la demande d'homologation EPA No d'homologation. 11556-151
Nom du produit: advantage II small cat
Liquide
Oui
Unités: mL
Site: Animal / Usage sur un animal domestique
Autre
Cat / Chat
Domestic Longhair
1
Homme
5.5
11
lbs
Cutanée
>1 wk <=1 mo / > 1 sem < = 1 mois
>1 wk <=1 mo / > 1 sem < = 1 mois
Système
>1 wk <=1 mo / > 1 sem < = 1 mois
Oui
Non
Mort
Treatment / Traitement
(p.ex. description des symptômes tels que la fréquence et la gravité
On 13 Oct 2016, the pruritus and skin lesions worsened. The cat was not examined by a veterinarian and the clinical signs continued. Follow up received on 7th Nov 2016: On 13 Oct 2016, the pruritus and skin lesions worsened. The cat was not examined by a veterinarian and the clinical signs continued. The owner administered another tube of Advantage II Small Cat (Imidacloprid-Pyriproxyfen) topically by the owner. This was again, an off label use of the product as it was a low dose for this cat. The clinical signs continued. On 05 Nov 2016, the cat was administered 1 tube of Advantage II Large Cat (Imidacloprid-Pyriproxyfen) topically by the owner. Approximately 30 minutes post application, the cat vocalized and died. The cat was examined by a veterinarian and pronounced dead on arrival. No necropsy was performed.
Mort
Pruritus on other than the application site is not anticipated with topical product administration. If any, sign would be localized at the application site. Skin lesions are not expected after product application. Moreover, signs were pre-existing. Further reported vocalization is very unspecific and may have numerous other causes, sign reported after re-application of product. Death is not expected after product application as inconsistent with pharmaco-toxicological product profile. Other causes are more probable. No signs of allergic/anaphylactic reaction reported. Product has wide margin of safety. Oral LD50 in rat is 642 mg/kg BW. 24-fold over dosage tolerated by cats without showing any side effect. Moreover, in this case, cat was administered low dose of the product. Time to onset is not suggestive of product relation. Animal involved in this case was in poor health condition, which may have further contributed to death of the animal. Even though no necropsy was performed, considering known product safety profile, a product relation is unlikely.